Development of potent monoclonal antibody auristatin conjugates for cancer therapySvetlana O. Doronina, Peter D. Senter, Damon L. Meyer et al.|Nature Biotechnology|2003Cited by 1.2k
cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activityJoseph A. Francisco, Alan F. Wahl, Charles G. Cerveny et al.|Blood|2003Cited by 918
Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic indexRobert P. Lyon, Peter D. Senter, Tim D. Bovee et al.|Nature Biotechnology|2015Cited by 521
Enhanced Activity of Monomethylauristatin F through Monoclonal Antibody Delivery: Effects of Linker Technology on Efficacy and ToxicitySvetlana O. Doronina, Peter D. Senter, Brian A. Mendelsohn et al.|Bioconjugate Chemistry|2005Cited by 511
Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugatesRobert P. Lyon, Peter D. Senter, Jocelyn R. Setter et al.|Nature Biotechnology|2014Cited by 445